Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation: the NCT Neuro Master Match (N2M2) pilot study
AbstractBackground. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma patients. Glioblastoma
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Neuro-Oncology
Year: 2017, Jahrgang: 20, Heft: 6, Pages: 826-837 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/nox216 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1093/neuonc/nox216 Verlag, Volltext: https://academic.oup.com/neuro-oncology/article/20/6/826/4641653 |
| Verfasserangaben: | Elke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, Anne Berberich, Daniel Schrimpf, Antje Wick, Jürgen Debus, Andreas Unterberg, Martin Bendszus, Christel Herold-Mende, David Capper, Irini Schenkel, Andreas Eisenmenger, Susan Dettmer, Benedikt Brors, Michael Platten, Stefan M. Pfister, Andreas von Deimling, David T.W. Jones, Wolfgang Wick, and Felix Sahm |
| Zusammenfassung: | AbstractBackground. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma patients. Glioblastoma |
|---|---|
| Beschreibung: | Gesehen am 23.08.2018 Published: 18 November 2017 |
| Beschreibung: | Online Resource |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/nox216 |